News
PHAR
8.49
+5.46%
0.44
Weekly Report: what happened at PHAR last week (0407-0411)?
Weekly Report · 11h ago
Pharming price target lowered to EUR 2 from EUR 2.15 at RBC Capital
TipRanks · 04/07 19:05
Weekly Report: what happened at PHAR last week (0331-0404)?
Weekly Report · 04/07 10:25
Pharming Group Files 2024 Annual Report and Form 20-F
TipRanks · 04/03 10:27
Pharming Group: Small Dutch Company With Strong Revenues
Seeking Alpha · 04/01 12:45
Weekly Report: what happened at PHAR last week (0324-0328)?
Weekly Report · 03/31 10:32
Weekly Report: what happened at PHAR last week (0317-0321)?
Weekly Report · 03/24 10:25
Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Dow Jones · 03/21 12:04
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
Benzinga · 03/20 15:16
Pharming Group (PHAR) Receives a Buy from H.C. Wainwright
TipRanks · 03/20 14:16
Pharming Doses First Patient In Phase II Trial of Leniolisib For CVID With Immune Dysregulation
Benzinga · 03/20 06:40
Weekly Report: what happened at PHAR last week (0310-0314)?
Weekly Report · 03/17 10:31
What Analysts Are Saying About Pharming Stock
Benzinga · 03/14 19:00
Pharming Group Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/14 16:47
Pharming Group Price Target Raised to $39.00/Share From $30.00 by Oppenheimer
Dow Jones · 03/14 16:47
Oppenheimer Maintains Outperform on Pharming, Raises Price Target to $39
Benzinga · 03/14 16:37
Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 10:54
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
Benzinga · 03/14 10:44
Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth
Seeking Alpha · 03/13 23:45
More
Webull provides a variety of real-time PHAR stock news. You can receive the latest news about Pharming Group N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHAR
More
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.